Praxis Precision Medicines (NASDAQ:PRAX) Upgraded at Wells Fargo & Company

Praxis Precision Medicines logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wells Fargo upgraded Praxis Precision Medicines to “strong buy” from “hold” and set a $509 price target, implying 66.85% upside from the stock’s current price.
  • Analyst views are mostly positive: MarketBeat reports a consensus “Buy” rating and a $656.42 average price target, though two analysts rate the stock “Sell.”
  • Praxis reported a quarterly loss of $3.23 per share, narrower than analysts’ expected loss of $3.54 per share.
  • MarketBeat previews top five stocks to own in December.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) was upgraded by equities research analysts at Wells Fargo & Company from a "hold" rating to a "strong-buy" rating in a research note issued on Tuesday, MarketBeat.com reports. The firm currently has a $509.00 price objective on the stock. Wells Fargo & Company's price target would suggest a potential upside of 66.85% from the stock's current price.

Several other brokerages have also issued reports on PRAX. BTIG Research reiterated a "buy" rating and set a $826.00 price objective on shares of Praxis Precision Medicines in a report on Monday, November 9th. Royal Bank Of Canada upped their target price on Praxis Precision Medicines from $462.00 to $478.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 10th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Praxis Precision Medicines in a research report on Monday, August 24th. The Goldman Sachs Group reissued a "buy" rating and set a $575.00 price objective (up from $470.00) on shares of Praxis Precision Medicines in a research report on Friday, August 21st. Finally, Raymond James Financial restated a "strong-buy" rating and set a $945.00 target price on shares of Praxis Precision Medicines in a research note on Monday, August 17th. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $656.42.

Read Our Latest Stock Analysis on Praxis Precision Medicines

Praxis Precision Medicines Stock Performance

Praxis Precision Medicines stock opened at $305.06 on Tuesday. Praxis Precision Medicines has a twelve month low of $160.11 and a twelve month high of $392.70. The firm has a market cap of $8.53 billion, a PE ratio of -23.83 and a beta of 2.85. The firm's 50 day moving average price is $288.12 and its two-hundred day moving average price is $314.34.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last issued its earnings results on Monday, November 9th. The company reported ($3.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.54) by $0.31. Equities analysts anticipate that Praxis Precision Medicines will post -13.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PRAX. Seven Fleet Capital Management LP bought a new stake in Praxis Precision Medicines in the second quarter valued at about $2,524,000. Readystate Asset Management LP bought a new position in Praxis Precision Medicines during the second quarter worth about $3,531,000. Swiss National Bank lifted its stake in Praxis Precision Medicines by 15.3% during the first quarter. Swiss National Bank now owns 46,700 shares of the company's stock worth $15,046,000 after purchasing an additional 6,200 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Praxis Precision Medicines during the second quarter worth about $2,698,000. Finally, Orbimed Advisors LLC grew its stake in shares of Praxis Precision Medicines by 82.5% in the 1st quarter. Orbimed Advisors LLC now owns 172,500 shares of the company's stock valued at $55,578,000 after purchasing an additional 78,000 shares during the period. Institutional investors own 67.84% of the company's stock.

About Praxis Precision Medicines

(Get Free Report)

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.

Featured Stories

Analyst Recommendations for Praxis Precision Medicines (NASDAQ:PRAX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Praxis Precision Medicines Right Now?

Before you consider Praxis Precision Medicines, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.

While Praxis Precision Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines